Share
.webp)
.webp)
.webp)
.webp)
Dennis Hom
ProQR Therapeutics N.V., a biotechnology company pioneering transformative RNA editing therapies with its proprietary Axiomer™ platform, has announced two strategic leadership appointments to support its advancement into the clinical stage.
Dennis Hom joins as Chief Financial Officer (CFO) and Dr. Cristina Lopez Lopez, M.D., Ph.D., assumes the role of Chief Medical Officer (CMO).
Dennis Hom brings over 25 years of financial and corporate leadership in biotech. Most recently serving as CFO and Head of Corporate Development at Sagimet Biosciences, he spearheaded its IPO and a major licensing deal. His extensive experience also includes senior business development roles at Amgen and Novartis, following a successful investment banking career at Hambrecht & Quist/JP Morgan, where he advised biotech firms on capital and M&A strategies. At ProQR, Hom will lead corporate finance, investor relations, and business development, building on a track record of raising over US$4.5 billion and executing US$57 billion in deals.
These leadership changes mark a significant step in ProQR’s strategic transition to a focused RNA editing Therapeutics Company, as former CFO Jurriaan Dekkers and Chief Corporate Development Officer René Beukema step down. Both will stay on during a transition period to ensure continuity.
